1. Pink Sheet
  2. >>Market Access
  3. >>Health Technology Assessment

Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math

 
• By Mary Jo Laffler

Amgen walks through its price-setting model for PCSK9 inihibitor Repatha and says new outcomes data just presented at ACC provides more evidence that "prices that exist in the market are indeed value-based."

As payers and others grapple with what "value" means in the evolving drug reimbursement environment – and how to calculate it, Amgen Inc. is making the case that its price for the PCSK9 inihibitor Repatha (evolocumab) is backed up by its value-assessment approach and outcomes data.

In tandem with presenting the final results from its FOURIER cardiovascular outcomes trial at the American College of Cardiology annual meeting on March 17, Amgen highlighted new steps it will take with payers to overcome coverage restrictions for Repatha

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

More from Market Access

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 
• By Derrick Gingery

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By Cathy Kelly

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

Most Favored Nation Pricing Policy Floated In Medicaid, Coming Back To Medicare?

 
• By Cathy Kelly

President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention.